Hologic, Inc. (NASDAQ:HOLX) Stock Position Reduced by Artemis Investment Management LLP

Artemis Investment Management LLP reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 34.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,211 shares of the medical equipment provider’s stock after selling 1,716 shares during the period. Artemis Investment Management LLP’s holdings in Hologic were worth $231,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Wolff Wiese Magana LLC bought a new position in shares of Hologic in the 3rd quarter worth about $25,000. General Partner Inc. bought a new position in Hologic in the fourth quarter worth about $26,000. First Horizon Advisors Inc. boosted its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the period. Sunbelt Securities Inc. bought a new position in shares of Hologic during the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC raised its position in shares of Hologic by 330.2% during the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 0.3 %

Shares of NASDAQ:HOLX opened at $69.73 on Monday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 12-month low of $68.61 and a 12-month high of $84.67. The firm has a fifty day moving average of $74.84 and a two-hundred day moving average of $78.41. The firm has a market capitalization of $15.82 billion, a P/E ratio of 20.94, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 earnings per share. On average, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Buying and Selling at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.75% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of several analyst reports. Royal Bank of Canada boosted their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Monday, January 13th. Leerink Partners dropped their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Raymond James boosted their price objective on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Finally, Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.